Moustafa, H.A.M.; Elbery, F.H.; Al Meslamani, A.Z.; Okda, S.M.; Alsfouk, B.A.; Kassem, A.B.
Evaluating the Use of Inhaled Budesonide and Ipratropium Bromide Combination in Patients at High Risk of Acute Respiratory Distress Syndrome Development: A Randomized Controlled Trial. Pharmaceuticals 2025, 18, 412.
https://doi.org/10.3390/ph18030412
AMA Style
Moustafa HAM, Elbery FH, Al Meslamani AZ, Okda SM, Alsfouk BA, Kassem AB.
Evaluating the Use of Inhaled Budesonide and Ipratropium Bromide Combination in Patients at High Risk of Acute Respiratory Distress Syndrome Development: A Randomized Controlled Trial. Pharmaceuticals. 2025; 18(3):412.
https://doi.org/10.3390/ph18030412
Chicago/Turabian Style
Moustafa, Hebatallah Ahmed Mohamed, Faten H. Elbery, Ahmad Z. Al Meslamani, Sherouk M. Okda, Bshra A. Alsfouk, and Amira B. Kassem.
2025. "Evaluating the Use of Inhaled Budesonide and Ipratropium Bromide Combination in Patients at High Risk of Acute Respiratory Distress Syndrome Development: A Randomized Controlled Trial" Pharmaceuticals 18, no. 3: 412.
https://doi.org/10.3390/ph18030412
APA Style
Moustafa, H. A. M., Elbery, F. H., Al Meslamani, A. Z., Okda, S. M., Alsfouk, B. A., & Kassem, A. B.
(2025). Evaluating the Use of Inhaled Budesonide and Ipratropium Bromide Combination in Patients at High Risk of Acute Respiratory Distress Syndrome Development: A Randomized Controlled Trial. Pharmaceuticals, 18(3), 412.
https://doi.org/10.3390/ph18030412